224.24

1.81% 3.97

Cardinal Health Inc (CAH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Cardinal Health Inc stock is traded at $224.24, with a volume of 518.19K. It is up +1.81% in the last 24 hours and up +11.51% over the past month. Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Previous Close:

$220.27

Open:

$220.96

24h Volume:

518.19K

Relative Volume:

0.26

Market Cap:

$52.76B

Revenue:

$244.67B

Net Income/Loss:

$1.68B

P/E Ratio:

32.27

EPS:

6.9487

Net Cash Flow:

$5.51B

1W Performance:

+8.42%

1M Performance:

+11.51%

6M Performance:

+42.24%

1Y Performance:

+74.67%

1-Day Range:

$219.72

$224.86

1-Week Range:

$212.03

$230.81

52-Week Range:

$120.72

$230.81

Cardinal Health Inc Stock (CAH) Company Profile

Name

Cardinal Health Inc

Sector

Healthcare (1115)

Industry

Medical Distribution (12)

Phone

(614) 757-3033

Address

7000 CARDINAL PLACE, DUBLIN, OH

Employee

57,700

Twitter

@cardinalhealth

Next Earnings Date

2024-11-01

Latest SEC Filings

CAH's Discussions on Twitter

Compare CAH vs MCK, COR, HSIC, AHG

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CAH Cardinal Health Inc	224.21	51.83B	244.67B	1.68B	5.51B	6.9487
MCK Mckesson Corporation	940.72	114.55B	397.96B	4.55B	9.64B	34.77
COR Cencora Inc	364.31	70.03B	325.78B	1.64B	3.61B	8.3139
HSIC Henry Schein Inc	81.30	9.54B	12.50B	314.00M	421.00M	2.44
AHG Akso Health Group Adr	1.41	793.60M	2.22M	-5.63M	-1.68M	-0.24

Cardinal Health Inc Stock (CAH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-09-26	Upgrade	Citigroup	Neutral → Buy
Dec-09-25	Initiated	Barclays	Overweight
Jun-03-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-05-25	Upgrade	Jefferies	Hold → Buy
Jan-08-25	Upgrade	TD Cowen	Hold → Buy
Jan-07-25	Upgrade	Evercore ISI	In-line → Outperform
Jan-06-25	Upgrade	BofA Securities	Neutral → Buy
Dec-13-24	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-04-24	Resumed	Mizuho	Outperform
Feb-26-24	Initiated	Leerink Partners	Outperform
Feb-09-24	Upgrade	Argus	Hold → Buy
Jan-03-24	Initiated	Barclays	Overweight
Dec-14-23	Initiated	Wells Fargo	Underweight
Jul-10-23	Downgrade	Evercore ISI	Outperform → In-line
Mar-31-23	Initiated	Citigroup	Neutral
Feb-03-23	Upgrade	Robert W. Baird	Neutral → Outperform
Nov-04-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-22-22	Resumed	Morgan Stanley	Overweight
May-26-22	Downgrade	Barclays	Overweight → Equal Weight
May-18-22	Upgrade	Evercore ISI	In-line → Outperform
Apr-12-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-01-22	Resumed	Credit Suisse	Neutral
Aug-06-21	Downgrade	Deutsche Bank	Buy → Hold
Aug-05-21	Downgrade	BofA Securities	Buy → Underperform
May-10-21	Downgrade	Robert W. Baird	Outperform → Neutral
Jan-08-21	Upgrade	Wolfe Research	Underperform → Peer Perform
Nov-02-20	Upgrade	Barclays	Equal Weight → Overweight
Sep-25-20	Upgrade	Deutsche Bank	Hold → Buy
Jul-20-20	Upgrade	Guggenheim	Neutral → Buy
May-15-20	Upgrade	UBS	Neutral → Buy
Apr-23-20	Resumed	Credit Suisse	Neutral
Mar-20-20	Upgrade	BofA/Merrill	Underperform → Buy
Feb-12-20	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-07-20	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-16-19	Downgrade	Guggenheim	Buy → Neutral
Sep-12-19	Initiated	Deutsche Bank	Hold
Aug-27-19	Downgrade	Argus	Buy → Hold
Aug-20-19	Upgrade	Guggenheim	Neutral → Buy
Apr-18-19	Initiated	Guggenheim	Neutral
Jan-17-19	Initiated	UBS	Neutral
Nov-16-18	Downgrade	Leerink Partners	Outperform → Mkt Perform
Apr-24-18	Upgrade	Leerink Partners	Mkt Perform → Outperform
Apr-02-18	Upgrade	Argus	Hold → Buy
Mar-08-18	Initiated	Barclays	Equal Weight
Feb-27-18	Resumed	BofA/Merrill	Underperform
Jan-05-18	Initiated	Evercore ISI	In-line

View All

Cardinal Health Inc Stock (CAH) Latest News

09:48 AM

Cardinal Health (NYSE:CAH) Given New $248.00 Price Target at Argus - MarketBeat

09:48 AM

Feb 10, 2026

Wells Fargo Raises Price Target for Cardinal Health (CAH) | CAH Stock News - GuruFocus

Feb 10, 2026

Nasogastric Tubes Market Is Booming Worldwide 2026-2033 | - openPR.com

Feb 10, 2026

Wells Fargo Adjusts Price Target on Cardinal Health to $256 From $237, Maintains Overweight Rating - marketscreener.com

Feb 10, 2026

Candriam S.C.A. Acquires 19,155 Shares of Cardinal Health, Inc. $CAH - MarketBeat

Feb 10, 2026

Feb 09, 2026

Fresh Look At Cardinal Health (CAH) Valuation After Mixed Recent Share Performance - Sahm

Feb 09, 2026

Earnings Winners: 2 Buy Rated Stocks Raising Guidance - Finviz

Feb 09, 2026

Lasix ONYU Gains Major Distributor Access Through Cardinal Health and Cencora - Pharmaceutical Commerce

Feb 09, 2026

Morgan Stanley raises Cardinal Health, Inc. (CAH) price target after strong Q2 - MSN

Feb 09, 2026

Morgan Stanley Raises Cardinal Health, Inc. (CAH) Price Target After Strong Q2 - Finviz

Feb 09, 2026

Cardinal Health CEO Jason Hollar says Central Ohio is key to achieving record revenueColumbus Business First - The Business Journals

Feb 09, 2026